# US 2018/0022812 A1 · Treatment of autoimmune disorders with cd154 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022812 A1
- Document ID: US20180022812A1
- Status: Published application
- Kind: A1
- Application number: 15/547,223
- Filed: 2015-04-27
- Published: 2018-01-25
- Earliest claimed: 2015-01-30
- Assignees: Ucb Biopharma Sprl
- Applicants: Ucb Biopharma Sprl
- Inventors: RUTH OLIVER; MIREN ZAMACONA
- Web page: https://patentgrep.com/patent/US20180022812A1

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/35: Valency
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method of treating an autoimmune, inflammatory, neurodegenerative or neuromuscular disorder in a mammalian subject comprising:
a) administering an initial loading dose of about 20-60 mg/kg of antibody or antibody fragment binding specifically to CD154 to a subject in need of such treatment; and
b) about 2 weeks after the initial loading dose administering a further dose or doses of about half of the initial loading dose with a frequency of about once every other week of antibody or antibody fragment binding specifically to CD154 to the subject in need of such treatment.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the initial loading dose is about 30 mg/kg and the further dose is about 15 mg/kg.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the antibody or antibody fragment binding specifically to CD154 is administered to the patient in need thereof at least for 12 weeks.

### Claim 21 (depends on 18)

The method according to claim 18, wherein said antibody or antibody fragment binding specifically to CD154 is a neutralizing antibody or antibody fragment.

### Claim 22 (depends on 18)

The method according to claim 18, wherein said antibody or antibody fragment specifically binding to CD154 has a dissociation constant for monovalent binding to CD40 of KD≦4.55 pM as determined by surface plasmon resonance.

### Claim 23 (depends on 18)

The method according to claim 18, wherein said antibody or antibody fragment specifically binding to CD154 comprises a light chain variable region (LCVR) having a CDR1, a CDR2 and a CDR3 comprising the amino acid sequence of SEQ ID NOs:1, 2 and 3, respectively, and a heavy chain variable region (HCVR) having a CDR1, a CDR2 and a CDR3 comprising the amino acid sequence of SEQ ID NOs: 4, 5 and 6, respectively.

### Claim 24 (depends on 23)

The method according to claim 23, wherein said antibody or antibody fragment specifically binding to CD154 exhibits monovalent binding to CD40, and has only one binding site that binds specifically CD154.

### Claim 25 (depends on 24)

The method according to claim 24, wherein said antibody or antibody fragment specifically binding to CD154 contains the VL chain sequence shown in SEQ ID NO:7 and the VH chain sequence shown in SEQ ID NO:8.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said antibody or antibody fragment specifically binding to CD154 has the light chain sequence shown in SEQ ID NO:9 and the heavy chain sequences shown in SEQ ID NO:10.

### Claim 27 (depends on 26)

The method according to claim 26, wherein said antibody or antibody fragment specifically binding to CD154 is a monovalent Fab′ having the light chain sequence shown in SEQ ID NO:9 and the heavy chain sequences shown in SEQ ID NO:10.

### Claim 28 (depends on 27)

The method according to claim 27, wherein said antibody or antibody fragment specifically binding to CD154 has
a) a maleimide group covalently linked to a single thiol group in the modified hinge region; a lysine residue is covalently linked to the maleimide group; and
b) a methoxypoly(ethyleneglycol) polymer having a molecular weight of approximately 20 KDa is attached to each of the amine groups on the lysine residue.

### Claim 29 (depends on 18)

The method according to claim 18, wherein said autoimmune, inflammatory, neurodegenerative or neuromuscular disorder systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, seronegative spondyloarthropathies, psoriasis, psoriatic arthritis, scleroderma, Sjögren's syndrome, multiple sclerosis, type I diabetes, autoimmune uveitis and nephrotic syndrome or vasculitis.

### Claim 30 (depends on 29)

The method according to claim 29, wherein said antibody or antibody fragment specifically binding to CD154 is administered to a subject having systemic lupus erythematosus (SLE) wherein the subject treated achieves an improvement from baseline of one or more of the indices selected from SLEDAI, BILAG and Global Physician assessment.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the subject treated achieves a SLEDAI Responder Index 4 (SRI-4).

### Claim 32 (depends on 29)

The method according to claim 29, wherein said subject has systemic lupus erythematosus (SLE) and wherein the subject treated achieves a 50% improvement from baseline of the SRI-50 index.

### Claim 33 (depends on 29)

The method according to claim 29, wherein said subject has systemic lupus erythematosus (SLE) and achieves an increase of 20%, 30%, 40%, 50%, 75% or 90% from baseline or normalization of complement C3 and C4 concentration, or a reduction of 20%, 30%, 40%, 50%, 75% or 90% of anti-double stranded DNA titre in serum.

### Claim 34 (depends on 29)

The method according to claim 29, wherein said subject has systemic lupus erythematosus (SLE) and wherein the subject reverts from seropositive to seronegative for anti-double stranded DNA antibodies.
